This segment focuses on the research, development, and commercialization of innovative therapies for ophthalmic diseases, particularly those affecting the retina. The primary focus is on ONS-5010/LYTENAVA™ (bevacizumab-gamma), a proprietary ophthalmic formulation of bevacizumab being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Research and development activities include conducting clinical trials to evaluate the safety and efficacy of ONS-5010, as well as exploring potential new indications and formulations. The segment aims to address the unmet needs in the treatment of retinal diseases by providing targeted therapies that improve patient outcomes and preserve vision. Future opportunities include expanding the market reach of ONS-5010 and developing new ophthalmic therapies through strategic partnerships and collaborations.